Stronger together: a new fusion protein boosts cancer immunotherapy
Advertisement
A newly developed molecule brings together two powerful Immunotherapy strategies in one treatment. Researchers at the University of Basel and University Hospital Basel have demonstrated that this fusion protein can both block the “do not attack” signal used by cancer cells and selectively activate tumor-fighting immune cells. This dual action could pave the way for more effective cancer therapies with fewer side effects.
Back in the early 1980s, Linda Taylor, just 33 years old, was diagnosed with advanced skin cancer and faced a grim prognosis. Luckily, she met Dr. Stephen Rosenberg from the National Cancer Institute in Bethesda, Maryland, who treated her with an experimental approach harnessing the body’s own immune system to fight the disease. In 1984, Taylor became the first patient ever to be cured through immunotherapy – a groundbreaking case that forever changed the landscape of cancer treatment.
That pioneering therapy relied on interleukin-2 (IL-2), a signaling molecule that activates many types of immune cells to attack tumors. IL-2 later became the first immunotherapy approved by the U.S. Food and Drug Administration (FDA). However, while effective, IL-2 therapy often causes severe side effects and can also stimulate regulatory T cells, which dampen the immune response instead of boosting it.
Fewer side effects, increased efficiency
To overcome these limitations, scientists have recently generated improved IL-2 variants designed to specifically target tumor-killing immune cells. The new fusion protein – developed by the pharmaceutical company Roche – takes this a step further by combining an IL-2 variant (IL-2v) with an antibody that binds to PD-1, a receptor found in high numbers on immune cells within tumors.
In Science Translational Medicine, a research team led by Professor Alfred Zippelius from the Department of Biomedicine reports promising results with that fusion protein using cancer and immune cells from lung cancer patients. The researchers showed that the molecule selectively activated immune cells isolated from patient tumors that directly target and destroy cancer cells, without triggering the suppressive regulatory T cells. Importantly, it also reawakened “exhausted” immune cells that had been rendered inactive by chronic stimulation in the tumor environment.
Blockage removal and activation
The fusion of the two components, PD-1 antibodies and IL-2v, has two advantages: The antibody guides IL-2v directly to the tumor site, where it activates the immune cells most capable of destroying cancer cells. At the same time, the antibody blocks the PD-1 pathway, which tumors use to suppress immune attack, effectively releasing the immune system’s brakes and allowing it to respond more aggressively.
“The tumor normally restricts the immune system, but the fusion molecule overcomes this inhibition and additionally activates the immune cells,” summarizes Dr. Clara Serger, one of the two co-first authors of the study.
The team’s findings provide crucial insights into how this innovative therapy works and may help guide further refinements. The fusion protein is currently being evaluated in an ongoing phase I clinical trial led by Roche.
Original publication
Irene Fusi, Clara Serger, Petra Herzig, Markus Germann, Michael T. Sandholzer, Nicole Oelgarth, Petra C. Schwalie, Leyla Don, Viola K. Vetter, Viktor H. Koelzer, Didier Lardinois, Henry Kao, Laura Codarri Deak, Pablo Umaña, Christian Klein, Aljaz Hojski, Marina Natoli, Alfred Zippelius; "PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer"; Science Translational Medicine, Volume 17
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
AI models for drug design fail in physics
Targeted protein degradation: Researchers find new way to combat harmful proteins in tumour cells - Domino effect in the fight against cancer
Chemistry meets biology: controlling artificial cell membranes through catalysis - Researchers develop an artificial metalloenzyme-based platform that enables programmable control of artificial membrane behavior
QIAGEN to acquire Parse Biosciences - Entering the age of single-cell AI
Setting the Course for AI-Assisted Radiology - Fraunhofer MEVIS and Radboud University Medical Center have founded the spin-off Plain Medical
Ancient viral DNA shapes modern human placentas - “It’s a reminder that there is much more to learn about our genome and how ancient infections can influence who we are today”
Analytica 2026: AI as a driver of digital transformation - Laboratory of the future in action
How the principle of cheese noodles helps against Alzheimer's
New deep-learning tool can tell if your salmon is wild or farmed
Bayer confirms 2025 Group outlook, progresses on strategic priorities - "Our organization continues to get leaner and more efficient, and we’re seeing benefits in terms of speed and focus"
Q3 2025: Merck Shows Solid Organic Growth Across All Sectors - Strong performance by Process Solutions, Rare Diseases and Semiconductor Solutions
